Literature DB >> 7273027

Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma.

J C Britell, C G Moertel, L K Kvols, M J O'Connell, J Rubin, A J Schutt.   

Abstract

Oral 6-thioguanine (6-TG) is an S-phase antimetabolite with significant activity against acute leukemia. Preliminary reports of activity of iv 6-TG indicated significant activity against advanced colorectal cancer. We conducted a phase II study of iv 6-TG in 29 patients with advanced measurable colorectal cancer. Only one transient partial response occurred. Toxic effects included mild myelosuppression, nausea, vomiting, and minor ECG changes. We discourage further use of iv 6-TG in the dose and schedule we used to treat advanced colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273027

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

Review 1.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

2.  6-Thioguanine: high-dose 2-H infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; M B van Leeuwen; J M van Baal; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.